USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pat...
October 24 2017 - 6:05AM
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
today announced that the U.S. Patent and Trademark Office (USPTO)
has issued a U.S. Patent to Achillion for ACH-4471. U.S. Patent No.
9,796,741, entitled “Aryl, Heteroaryl, and Heterocyclic Compounds
for Treatment of Complement Mediated Disorders,” has been granted
with claims to compositions of matter for ACH-4471 and additional
compounds that inhibit complement factor D activity, a key mediator
in the complement alternative pathway (AP). This issued patent will
be the eighth patent that the USPTO has granted to Achillion this
year on its complement factor D portfolio. Achillion currently has
over one hundred global patent applications and patents covering
its complement-related research program.
“We are very pleased with the granting of this
composition of matter patent for our first-in-class, oral
complement factor D inhibitor, ACH-4471,” commented Milind
Deshpande, Ph.D., President and Chief Executive Officer of
Achillion. “As a leader in complement alternative pathway biology,
we are building upon the recently reported efficacy data from our
ongoing phase 2 trial with ACH-4471 for untreated PNH, and look
forward to reporting the ongoing phase 2 14-day trial of ACH-4471
for patients with C3G / IC-MPGN.”
About the Achillion Alternative Pathway
Complement Factor D PlatformAchillion has leveraged its
internal discovery capabilities and a novel complement-related drug
development platform to develop small molecule factor D inhibitor
compounds that target the complement AP. Factor D is an essential
serine protease involved in the AP, a part of the innate immune
system. Achillion's complement platform is focused on seeking to
advance small molecule compounds that inhibit factor D and can
potentially be used in the treatment of immune-related diseases in
which the AP plays a critical role. Potential indications currently
being evaluated for these compounds include paroxysmal nocturnal
hemoglobinuria (PNH), C3 glomerulopathy (C3G), immune
complex-mediated membranoproliferative glomerulonephritis
(IC-MPGN), and geographic atrophy (GA), an advanced form of dry
age-related macular degeneration (dry AMD).
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is
a science-driven, patient-focused company seeking to leverage its
strengths across the continuum from discovery to commercialization
in its goal of providing better treatments for people with serious
diseases. The company employs a highly-disciplined discovery and
development approach that has allowed it to pursue best-in-class
oral antiviral therapy for chronic hepatitis C (HCV) and build a
platform of potent and specific complement factor D inhibitors for
AP-mediated diseases. Achillion is rapidly advancing its efforts to
become a fully-integrated pharmaceutical company with a goal of
bringing life-saving medicines to patients with rare diseases. More
information is available at http://www.achillion.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks, uncertainties and
other important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements.
Achillion may use words such as “expect,” “anticipate,” “project,”
“target,” “intend,” “plan,” “aim,” “believe,” “seek,” “estimate,”
“can,” “could” “focus,” “will,” “look forward,” “goal,” “may,”
“potential,” and similar expressions to identify such
forward-looking statements. These forward-looking statements also
include statements about: Achillion’s plans ongoing clinical
development plan including its phase 2 trial of ACH-4471 for
untreated PNH and its phase 2 trial of ACH-4471 for C3G / IC-MPGN;
Achillion’s ability to obtain and maintain patent protection for
its drug candidates and the expected benefit of its complement
factor D inhibitor intellectual property portfolio; the potential
benefits of, and potential indications for, Achillion’s compounds
that inhibit factor D; and statements concerning Achillion’s
strategic goals, efforts, plans, and prospects. Among the important
factors that could cause actual results to differ materially from
those indicated by such forward-looking statements are risks
relating to, among other things, Achillion’s ability to: advance
the preclinical and clinical development of its complement factor D
inhibitors under the timelines it projects in current and future
preclinical studies and clinical trials; obtain and maintain patent
protection for its drug candidates and the freedom to operate under
third party intellectual property, including completing the patent
process such that patents issue with respect to composition of
matter claims for compounds that inhibit complement factor D
activity; demonstrate in any current and future clinical trials the
requisite safety, efficacy and combinability of its drug
candidates; obtain and maintain necessary regulatory approvals;
establish commercial manufacturing arrangements; identify, enter
into and maintain collaboration and other commercial agreements
with third-parties; compete successfully in the markets in which it
seeks to develop and commercialize its product candidates and
future products; manage expenses; manage litigation; raise the
substantial additional capital needed to achieve its business
objectives; and successfully execute on its business strategies.
These and other risks are described in the reports filed by
Achillion with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-Q for the fiscal quarter
ended June 30, 2017, and any subsequent SEC filings.
In addition, any forward-looking statement in
this press release represents Achillion's views only as of the date
of this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Investors & Media:
Glenn Schulman, PharmD, MPH
Executive Director, Investor Relations
Achillion Pharmaceuticals, Inc.
Tel. (203) 752-5510
gschulman@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024